Literature DB >> 10654142

Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet.

A Signore1, M Chianelli, A Annovazzi, M Rossi, L Maiuri, M Greco, G Ronga, K E Britton, A Picarelli.   

Abstract

Coeliac disease is diagnosed by the presence of specific antibodies and a jejunal biopsy showing mucosal atrophy and mononuclear cell infiltration. Mucosal cell-mediated immune response is considered the central event in the pathogenesis of coeliac disease, and untreated coeliac patients show specific features of T-cell activation in the small intestine. Here we describe the use of iodine-123-interleukin-2 scintigraphy in coeliac patients as a non-invasive tool for detection of lymphocytic infiltration in the small bowel and its use for therapy follow-up, and we demonstrate the specificity of binding of labelled-IL2 to activated lymphocytes by ex-vivo autoradiography of jejunal biopsies. 123I-IL2 was administered i.v. [74 MBq (2 mCi)], and gamma camera images were acquired after 1 h. Ten patients were studied with 123I-IL2 scintigraphy at diagnosis and seven were also investigated after 12-19 months of gluten-free diet. Results were expressed as target-to-background radioactivity ratios in six different bowel regions before and after the diet. At the time of diagnosis all patients showed a significantly higher bowel uptake of 123I-IL2 than normal subjects (P < 0.003 in all regions). A significant correlation was found between jejunal radioactivity and the number of IL2R + ve lymphocytes per millimetre of jejunal mucosa as detected by immunostaining of jejunal biopsy (r2 = 0.66; P = 0.008). Autoradiography of jejunal biopsies confirmed that labelled-IL2 only binds to activated T-lymphocytes infiltrating the gut mucosa. After 1 year of the diet, bowel uptake of 123I-IL2 significantly decreased in five out of six regions (P < 0.03), although two patients still had a positive IL2 scintigraphy in one region. We conclude that 123I-IL2 scintigraphy is a sensitive non-invasive technique for assessing in vivo the presence of activated mononuclear cells in the bowel of patients affected by coeliac disease. Unlike jejunal biopsy, this method provides information from the whole intestine and gives a non-invasive measure of the effectiveness of the gluten-free diet.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10654142     DOI: 10.1007/pl00006657

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

1.  Identification of interleukin-2 for imaging atherosclerotic inflammation.

Authors:  Zahi A Fayad; Vardan Amirbekian; Jean-François Toussaint; Valentin Fuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

2.  99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.

Authors:  Alessio Annovazzi; Elena Bonanno; Marcello Arca; Calogero D'Alessandria; Antonella Marcoccia; Luigi G Spagnoli; Francesco Violi; Francesco Scopinaro; Giorgio De Toma; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-12       Impact factor: 9.236

3.  Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes.

Authors:  Alessio Annovazzi; Calogero D'Alessandria; Elena Bonanno; Stephen J Mather; Bart Cornelissen; Christophe van de Wiele; Rudi A Dierckx; Maurizio Mattei; Graziana Palmieri; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-27       Impact factor: 9.236

4.  (123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma.

Authors:  David Loose; Alberto Signore; Ludovicus Staelens; Katia Vanden Bulcke; Hubert Vermeersch; Rudi Andre Dierckx; Elena Bonanno; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-10       Impact factor: 9.236

5.  99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study.

Authors:  M Chianelli; S J Mather; A Grossman; R Sobnak; A Fritzberg; K E Britton; A Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

6.  99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Authors:  Alessio Annovazzi; Livia Biancone; Renato Caviglia; Marco Chianelli; Gabriela Capriotti; Stephen J Mather; Renzo Caprilli; Francesco Pallone; Francesco Scopinaro; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-09       Impact factor: 9.236

7.  Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients.

Authors:  Marta Opalinska; Tomasz Stompor; Dorota Pach; Renata Mikolajczak; Danuta Fedak; Marcin Krzanowski; Tomasz Rakowski; Anna Sowa-Staszczak; Boguslaw Glowa; Piotr Garnuszek; Michał Maurin; Urszula Karczmarczyk; Władysław Sulowicz; Alicja Hubalewska-Dydejczyk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

8.  Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics.

Authors:  Muammad Saeed Akhtar; Muhammad Babar Imran; Muhammad Afzal Nadeem; Abubaker Shahid
Journal:  Int J Pept       Date:  2012-05-17

9.  Synthesis and optimization of the labeling procedure of 99mTc-HYNIC-interleukin-2 for in vivo imaging of activated T lymphocytes.

Authors:  Calogero D'Alessandria; Valentina di Gialleonardo; Marco Chianelli; Stephen J Mather; Erik F J de Vries; Francesco Scopinaro; Rudi A Dierck; Alberto Signore
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

Review 10.  PET imaging of inflammation biomarkers.

Authors:  Chenxi Wu; Fang Li; Gang Niu; Xiaoyuan Chen
Journal:  Theranostics       Date:  2013-06-24       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.